Antigen News and Research

RSS

Prostate cancer patients with detectable post-operative PSA should receive more aggressive treatment

Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiation therapy treatment, according to a study published in the February 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology.

6 Feb 2015

Scientists investigate how T cells in colorectal tumors actively fight cancer

In recent years, a standard follow-up to colorectal cancer surgery has been to analyze the tumor tissue for the presence of immune cells. Finding high quantities of cytotoxic T cells, or "killer cells", means that there is a good chance that the disease will take a favorable course and that the risk of metastasis is comparatively low.

5 Feb 2015

Researchers suggest novel concept for developing vaccines against HIV and cancer

A experimental trial has shown successful by inducing serum in mice and has been highly neutralizing towards those ailments.

4 Feb 2015

Researchers develop optimised PSA screening programme for prostate cancer

As an indicator of prostate cancer, the PSA test is regarded in urology as highly controversial since it is not always unequivocal. A team of researchers from the Comprehensive Cancer Center at the MedUni Vienna and Vienna General Hospital has now developed a programme that compensates the shortfalls of PSA screening with methods from personalised medicine. As a result, prostate cancer screening is able to reach a new level of quality.

4 Feb 2015

New study helps explain how booster shots trigger immune 'memory' to improve

The last time you were in the doctor's office for a vaccine booster shot, did you wonder why you needed one? Exactly how booster shots offer long-term protection from viruses has long been a mystery to scientists.

3 Feb 2015

Serum Institute of India to use Genticel's Vaxiclase platform to develop pertussis vaccines

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces that it has licensed its Vaxiclase technology to Serum Institute of India Ltd., for use as a component in acellular multivalent combination vaccines including pertussis antigens.

3 Feb 2015

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today the receipt of the latest milestone payment of EUR 1 million from the Ovasave collaboration option, development and license agreement from Trizell (Trizell Holding SA).

30 Jan 2015

Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines

Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen.

30 Jan 2015

Researchers create customized soap bubbles that promote drug and vaccine delivery

When University of Maryland Professors Philip DeShong and Daniel Stein began tagging soap bubbles with biomolecules, they had no idea this technology would one day be poised to change the way drugs and vaccines fight against bacteria, viruses and cancer.

29 Jan 2015

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

The combination of age and baseline hepatitis B s-antigen level can help predict hepatitis B virus relapse in patients who achieve hepatitis B e-antigen loss or seroconversion following nucleos(t)ide analogue (NA) treatment, researchers report.

28 Jan 2015

Long-term TDF therapy offers sustained HBV suppression without resistance

Patients with chronic hepatitis B virus infection can achieve sustained viral suppression with long-term tenofovir disoproxil fumarate treatment without developing resistance, shows a 7-year study.

28 Jan 2015

Study: Targeted biopsy technique better than standard biopsy at detecting high-risk prostate cancer

Among men undergoing biopsy for suspected prostate cancer, targeted magnetic resonance/ultrasound fusion biopsy, compared with a standard biopsy technique, was associated with increased detection of high-risk prostate cancer and decreased detection of low-risk prostate cancer, according to a study in the January 27 issue of JAMA.

28 Jan 2015

Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

27 Jan 2015

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.

23 Jan 2015

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present at the Cell & Gene Therapy Forum 2015, January 26 - 28, 2015 at Grand Hayatt in Washington DC, United States.

23 Jan 2015

New discovery may help doctors develop better treatments for brain, spinal cord injuries

In a discovery that could dramatically affect the treatment of brain and spinal cord injuries, researchers have identified a previously unknown, beneficial immune response that occurs after injury to the central nervous system.

23 Jan 2015

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, announces significant progress in its drug discovery collaboration with AstraZeneca.

22 Jan 2015

Researchers explore how M6P deficiency affects different kinds of immune cells

A group of white blood cells known as B cells, which play a key role in the human immune response, need a protein-targeting signal called mannose 6-phosphate (M6P) in order to proliferate, differentiate, and present immune cell-activating antigens, according to a study in The Journal of Cell Biology.

20 Jan 2015

Tübingen researchers develop new way of labeling T-cells

To better understand what happens during immune reactions in the body, researchers at Tübingen University have developed a new way of labeling T-cells, allowing them to track the T-cell movement in mice using non-invasive positron emission technology (PET).

19 Jan 2015

Researchers identify clusters of underimmunization, vaccine refusal in Northern California

Researchers used spatial analysis software and electronic medical records to identify clusters of underimmunization and vaccine refusal among Kaiser Permanente members in Northern California, according to a study published today in the journal Pediatrics.

19 Jan 2015

Antigen News and Research

Prostate cancer patients with detectable post-operative PSA should receive more aggressive treatment

Scientists investigate how T cells in colorectal tumors actively fight cancer

Researchers suggest novel concept for developing vaccines against HIV and cancer

Researchers develop optimised PSA screening programme for prostate cancer

New study helps explain how booster shots trigger immune 'memory' to improve

Serum Institute of India to use Genticel's Vaxiclase platform to develop pertussis vaccines

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines

Researchers create customized soap bubbles that promote drug and vaccine delivery

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

Long-term TDF therapy offers sustained HBV suppression without resistance

Study: Targeted biopsy technique better than standard biopsy at detecting high-risk prostate cancer

Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

New discovery may help doctors develop better treatments for brain, spinal cord injuries

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Researchers explore how M6P deficiency affects different kinds of immune cells

Tübingen researchers develop new way of labeling T-cells

Researchers identify clusters of underimmunization, vaccine refusal in Northern California

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics